{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:39:33Z","timestamp":1773297573222,"version":"3.50.1"},"reference-count":124,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2015,2,16]],"date-time":"2015-02-16T00:00:00Z","timestamp":1424044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pediatric hepatoblastoma (HB) is commonly treated by neoadjuvant chemotherapy and surgical tumor resection according to international multicenter trial protocols. Complete tumor resection is essential and survival rates up to 95% have now been achieved in those tumors classified as standard-risk HB. Drug resistance and occurrence of metastases remain the major challenges in the treatment of HB, especially in high-risk tumors. These conditions urgently require the development of alternative therapeutic strategies. One of those alternatives is the modulation of apoptosis in HB cells. HBs regularly overexpress anti-apoptotic proteins of the Bcl-family in comparison to healthy liver tissue. This fact may contribute to the development of chemoresistance of HB cells. Synthetic small inhibitory molecules with BH3-mimetic effects, such as ABT-737 and obatoclax, enhance the susceptibility of tumor cells to different cytotoxic drugs and thereby affect initiator proteins of the apoptosis cascade via the intrinsic pathway. Besides additive effects on HB cell viability when used in combination with cytotoxic drugs, BH3-mimetics also play a role in preventing metastasation by reducing adhesion and inhibiting cell migration abilities. Presumably, including additive BH3-mimetic drugs into existing therapeutic regimens in HB patients might allow dose reduction of established cytotoxic drugs and thereby associated immanent side effects, while maintaining the antitumor activity. Furthermore, reduction of tumor growth and inhibition of tumor cell dissemination may facilitate complete surgical tumor resection, which is mandatory in this tumor type resulting in improved survival rates in high-risk HB. Currently, there are phase I and phase II clinical trials in several cancer entities using this potential target. This paper reviews the available literature regarding the use of BH3-mimetic drugs as single agents or in combination with chemotherapy in various malignancies and focuses on results in HB cells.<\/jats:p>","DOI":"10.3390\/ijms16024190","type":"journal-article","created":{"date-parts":[[2015,2,16]],"date-time":"2015-02-16T10:30:38Z","timestamp":1424082638000},"page":"4190-4208","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Role of BH3-Mimetic Drugs in the Treatment of  Pediatric Hepatoblastoma"],"prefix":"10.3390","volume":"16","author":[{"given":"Justus","family":"Lieber","sequence":"first","affiliation":[{"name":"Department of Pediatric Surgery and Pediatric Urology, University Children's Hospital,  Hoppe-Seyler-Strasse 1, T\u00fcbingen D-72076, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorin","family":"Armeanu-Ebinger","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery and Pediatric Urology, University Children's Hospital,  Hoppe-Seyler-Strasse 1, T\u00fcbingen D-72076, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery and Pediatric Urology, University Children's Hospital,  Hoppe-Seyler-Strasse 1, T\u00fcbingen D-72076, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2015,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.ejca.2006.05.011","article-title":"Liver cancer in european children: Incidence and survival, 1978\u20131997. Report from the automated childhood cancer information system project","volume":"42","author":"Stiller","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1634\/theoncologist.2008-0011","article-title":"Liver tumors in children","volume":"13","author":"Litten","year":"2008","journal-title":"Oncologist"},{"key":"ref_3","first-page":"809","article-title":"Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma","volume":"74","author":"Pietsch","year":"1996","journal-title":"Lab. Investig."},{"key":"ref_4","first-page":"1","article-title":"Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma","volume":"67","author":"Doi","year":"1976","journal-title":"Gann"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1200\/JCO.2002.07.400","article-title":"Treatment of unresectable and metastatic hepatoblastoma: A pediatric oncology group phase II study","volume":"20","author":"Katzenstein","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2003.06.003","article-title":"Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the international society of paediatric oncology\u2014SIOPEL 2","volume":"40","author":"Perilongo","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/11597740-000000000-00000","article-title":"Current and future management strategies for relapsed or progressive hepatoblastoma","volume":"14","author":"Venkatramani","year":"2012","journal-title":"Paediatr. Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.sempedsurg.2005.11.004","article-title":"Management of liver tumors in childhood","volume":"15","year":"2006","journal-title":"Semin. Pediatr. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/mpo.2950130405","article-title":"Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma","volume":"13","author":"Douglass","year":"1985","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0959-8049(99)00049-0","article-title":"Liver tumours","volume":"35","author":"Perilongo","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.2005.07.145","article-title":"Predictive value of the pretreatment extent of disease system in hepatoblastoma: Results from the international society of pediatric oncology liver tumor study group SIOPEL-1 study","volume":"23","author":"Aronson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/MOP.0000000000000042","article-title":"Hepatoblastoma state of the art: Pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation","volume":"26","author":"Meyers","year":"2014","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0959-8049(00)00074-5","article-title":"Pretreatment prognostic factors for children with hepatoblastoma\u2014Results from the international society of paediatric oncology (SIOP) study SIOPEL 1","volume":"36","author":"Brown","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJMoa0810613","article-title":"Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","volume":"361","author":"Perilongo","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.2009.22.4857","article-title":"Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: Final results of the SIOPEL-3HR study","volume":"28","author":"Zsiros","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/cncr.10632","article-title":"Pretreatment prognostic factors and treatment results in children with hepatoblastoma: A report from the german cooperative pediatric liver tumor study HB 94","volume":"95","author":"Fuchs","year":"2002","journal-title":"Cancer"},{"key":"ref_17","first-page":"159","article-title":"Differentiated treatment protocols for high- and standard-risk hepatoblastoma\u2014An interim report of the german liver tumor study HB99","volume":"215","author":"Haberle","year":"2003","journal-title":"Klin. Padiatr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.2005.02.6013","article-title":"Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma","volume":"24","author":"Malogolowkin","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00383-002-0906-0","article-title":"Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma","volume":"19","author":"Matsunaga","year":"2003","journal-title":"Pediatr. Surg. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1200\/JCO.2000.18.14.2665","article-title":"Randomized comparison of cisplatin\/vincristine\/fluorouracil and cisplatin\/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the children\u2019s cancer group and the pediatric oncology group","volume":"18","author":"Ortega","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2000.18.22.3819","article-title":"Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach\u2014Results of the first prospective study of the international society of pediatric oncology","volume":"18","author":"Pritchard","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","article-title":"Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): A prospective, single-arm, feasibility study","volume":"14","author":"Zsiros","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2005.02.004","article-title":"Guidelines for surgical treatment of hepatoblastoma in the modern era\u2014Recommendations from the childhood liver tumour strategy group of the international society of paediatric oncology (SIOPEL)","volume":"41","author":"Czauderna","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1399-3046.2005.00354.x","article-title":"Liver transplantation for hepatoblastoma: Indications and contraindications in the modern era","volume":"9","author":"Otte","year":"2005","journal-title":"Pediatr. Transplant."},{"key":"ref_25","first-page":"1261","article-title":"Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by akt activation","volume":"36","author":"Grotegut","year":"2010","journal-title":"Int. J. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/pbc.21956","article-title":"Adenovirus-mediated cytosine deaminase\/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro","volume":"53","author":"Warmann","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/bjc.2012.539","article-title":"Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts","volume":"108","author":"Eicher","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1158\/1078-0432.CCR-08-2878","article-title":"Activation of phosphatidylinositol-3'-kinase\/Akt signaling is essential in hepatoblastoma survival","volume":"15","author":"Hartmann","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","article-title":"Mechanisms of proteasome inhibitor action and resistance in cancer","volume":"11","author":"McConkey","year":"2008","journal-title":"Drug Resist. Updat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/138920109787315123","article-title":"Molecular targets for epigenetic therapy of cancer","volume":"10","author":"Humeniuk","year":"2009","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s11095-009-9895-1","article-title":"Programmed cell death pathways and current antitumor targets","volume":"26","author":"Tan","year":"2009","journal-title":"Pharm. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jss.2007.03.054","article-title":"Bcl-2 gene silencing in pediatric epithelial liver tumors","volume":"144","author":"Warmann","year":"2008","journal-title":"J. Surg. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/pbc.20330","article-title":"Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with beckwith-wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue","volume":"45","author":"Kobrinsky","year":"2005","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/pbc.20404","article-title":"Allogeneic graft-versus-hepatoblastoma effect","volume":"46","author":"Inaba","year":"2006","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1158\/0008-5472.CAN-04-4252","article-title":"Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate","volume":"65","author":"Armeanu","year":"2005","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/liv.12011","article-title":"The activity of gammadelta T cells against paediatric liver tumour cells and spheroids in cell culture","volume":"33","author":"Hoh","year":"2013","journal-title":"Liver Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1582-4934.2008.00563.x","article-title":"Oncolytic virotherapy for advanced liver tumours","volume":"13","author":"Chang","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00383-005-1573-8","article-title":"In vitro gene targeting in human hepatoblastoma","volume":"22","author":"Warmann","year":"2006","journal-title":"Pediatr. Surg. Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/(SICI)1097-0215(19971219)74:6<593::AID-IJC6>3.0.CO;2-P","article-title":"Prognostic factors and staging systems in childhood hepatoblastoma","volume":"74","author":"Hecker","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0021-9258(17)42175-2","article-title":"Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair","volume":"269","author":"Chu","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jpedsurg.2008.10.088","article-title":"Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies","volume":"44","author":"Oue","year":"2009","journal-title":"J. Pediatr. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3109\/07357909409021413","article-title":"Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors","volume":"12","author":"Pommier","year":"1994","journal-title":"Cancer Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","article-title":"The role of glutathione-S-transferase in anti-cancer drug resistance","volume":"22","author":"Townsend","year":"2003","journal-title":"Oncogene"},{"key":"ref_44","first-page":"6788","article-title":"Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome","volume":"60","author":"Sigal","year":"2000","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: From pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1038\/onc.2009.52","article-title":"Mimicking the BH3 domain to kill cancer cells","volume":"27","author":"Chonghaile","year":"2008","journal-title":"Oncogene"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/374733a0","article-title":"Induction of apoptosis by the Bcl-2 homologue bak","volume":"374","author":"Chittenden","year":"1995","journal-title":"Nature"},{"key":"ref_48","first-page":"665","article-title":"Bcl-w, a novel member of the Bcl-2 family, promotes cell survival","volume":"13","author":"Gibson","year":"1996","journal-title":"Oncogene"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","article-title":"Puma, a novel proapoptotic gene, is induced by p53","volume":"7","author":"Nakano","year":"2001","journal-title":"Mol. Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1101\/gad.14.16.2060","article-title":"Tbid, a membrane-targeted death ligand, oligomerizes bak to release cytochrome c","volume":"14","author":"Wei","year":"2000","journal-title":"Genes Dev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","article-title":"Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis","volume":"288","author":"Oda","year":"2000","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1128\/MCB.20.3.929-935.2000","article-title":"Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane","volume":"20","author":"Eskes","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.cdd.4400783","article-title":"Pro-apoptotic cascade activates bid, which oligomerizes Bak or Bax into pores that result in the release of cytochrome c","volume":"7","author":"Korsmeyer","year":"2000","journal-title":"Cell Death Differ."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/ncb1499","article-title":"Hierarchical regulation of mitochondrion-dependent apoptosis by Bcl-2 subfamilies","volume":"8","author":"Kim","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","article-title":"Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics","volume":"2","author":"Letai","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-08-0144","article-title":"Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy","volume":"15","author":"Kang","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The Bcl-2 protein family: Opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.biocel.2009.11.015","article-title":"Cellular FLICE-inhibitory protein (c-FLIP) signalling: A key regulator of receptor-mediated apoptosis in physiologic context and in cancer","volume":"42","author":"Bagnoli","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/156800908783497087","article-title":"Cellular FLICE-like inhibitory protein (c-FLIP): A novel target for cancer therapy","volume":"8","author":"Safa","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.humpath.2008.10.022","article-title":"Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways","volume":"40","author":"Adesina","year":"2009","journal-title":"Hum. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/pbc.22740","article-title":"Inhibition of Bcl-2 and Bcl-x enhances chemotherapy sensitivity in hepatoblastoma cells","volume":"55","author":"Lieber","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_62","first-page":"2194","article-title":"Proteasome inhibition overcomes trail resistance in human hepatoblastoma cells","volume":"4","author":"Fuchs","year":"2012","journal-title":"Front. Biosci."},{"key":"ref_63","first-page":"3049","article-title":"Antisense oligonucleotides suppress B-cell lymphoma growth in a scid-hu mouse model","volume":"9","author":"Cotter","year":"1994","journal-title":"Oncogene"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"20453","DOI":"10.1074\/jbc.C300138200","article-title":"Identification of chelerythrine as an inhibitor of bclxl function","volume":"278","author":"Chan","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/sj.cdd.4401937","article-title":"Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins","volume":"13","author":"Zhai","year":"2006","journal-title":"Cell Death Differ."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1074\/jbc.M111.334532","article-title":"Discovery of marinopyrrole a (maritoclax) as a selective MCL-1 antagonist that overcomes ABT-737 resistance by binding to and targeting MCL-1 for proteasomal degradation","volume":"287","author":"Doi","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/381335a0","article-title":"X-ray and nmr structure of human Bcl-xl, an inhibitor of programmed cell death","volume":"381","author":"Muchmore","year":"1996","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/pbc.21433","article-title":"Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program","volume":"50","author":"Lock","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10637-013-9999-7","article-title":"A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer","volume":"32","author":"Schelman","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e108694","DOI":"10.1371\/journal.pone.0108694","article-title":"A multicenter phase I\/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia","volume":"9","author":"Schimmer","year":"2014","journal-title":"PLoS One"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Modugno, M., Banfi, P., Gasparri, F., Borzilleri, R., Carter, P., Cornelius, L., Gottardis, M., Lee, V., Mapelli, C., and Naglich, J.G. (2014). MCL-1 antagonism is a potential therapeutic strategy in a subset of solid cancers. Exp. Cell. Res.","DOI":"10.1016\/j.yexcr.2014.11.022"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737140.2015.990442","article-title":"Progress in the treatment of elderly\/unfit chronic lymphocytic leukemia patients: Results of the german CLL-11 trial","volume":"15","author":"Molica","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clml.2014.04.007","article-title":"A phase ii, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia","volume":"14","author":"Arellano","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10549-009-0343-z","article-title":"Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells","volume":"119","author":"Arisan","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1158\/1535-7163.MCT-08-1078","article-title":"Tw-37, a small-molecule inhibitor of Bcl-2, mediates s-phase cell cycle arrest and suppresses head and neck tumor angiogenesis","volume":"8","author":"Ashimori","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","article-title":"Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic Gx15-070 (obatoclax)","volume":"68","author":"Konopleva","year":"2008","journal-title":"Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/leu.2009.151","article-title":"The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia","volume":"23","author":"Mason","year":"2009","journal-title":"Leukemia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-06-1574","article-title":"Preclinical studies of Tw-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1","volume":"13","author":"Mohammad","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.leukres.2006.11.010","article-title":"HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells","volume":"31","author":"Oliver","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/1078-0432.CCR-06-1526","article-title":"The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan","volume":"13","author":"Trudel","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1530\/ERC-14-0268","article-title":"Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering BCL2A1 and MCL1 overexpression","volume":"21","author":"Champa","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e106571","DOI":"10.1371\/journal.pone.0106571","article-title":"Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells","volume":"9","author":"Koehler","year":"2014","journal-title":"PLoS One"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/cdd.2009.48","article-title":"Different forms of cell death induced by putative Bcl2 inhibitors","volume":"16","author":"Vogler","year":"2009","journal-title":"Cell Death Differ."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00383-011-2988-z","article-title":"Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells","volume":"28","author":"Lieber","year":"2011","journal-title":"Pediatr. Surg. Int."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3892\/or.2012.2150","article-title":"Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737","volume":"29","author":"Lieber","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/1471-2407-11-362","article-title":"The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma","volume":"11","author":"Lieber","year":"2011","journal-title":"BMC Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.molcel.2009.09.030","article-title":"Stepwise activation of Bax and Bak by tBid, Bim, and puma initiates mitochondrial apoptosis","volume":"36","author":"Kim","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s10495-010-0515-7","article-title":"Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death","volume":"15","author":"Skommer","year":"2010","journal-title":"Apoptosis"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1083\/jcb.144.5.903","article-title":"Cell damage-induced conformational changes of the pro-apoptotic protein bak in vivo precede the onset of apoptosis","volume":"144","author":"Griffiths","year":"1999","journal-title":"J. Cell Biol."},{"key":"ref_91","unstructured":"Analysis, R.R.D.f.G.E.. Available online: http:\/\/157.82.78.238\/refexa\/main_search.Jsp%5D."},{"key":"ref_92","unstructured":"E-MEXP-1851, D.. Available online: http:\/\/www.Ebi.Ac.Uk\/arrayexpress%5D."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1200\/JCO.2006.09.7204","article-title":"Redefining the role of doxorubicin for the treatment of children with hepatoblastoma","volume":"26","author":"Malogolowkin","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.97.13.7124","article-title":"Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells","volume":"97","author":"Wang","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1124\/jpet.114.212910","article-title":"Inhibition of phosphatidylinositol 3-kinase\/Akt signaling by Nvp-Bkm120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells","volume":"350","author":"Jane","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/sj.leu.2403102","article-title":"HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia\/lymphoma cells, and enhances cytarabine-induced cell death","volume":"17","author":"Lickliter","year":"2003","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1158\/0008-5472.CAN-05-2097","article-title":"The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death","volume":"66","author":"Manero","year":"2006","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1038\/sj.onc.1209515","article-title":"Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma","volume":"25","author":"Niizuma","year":"2006","journal-title":"Oncogene"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1124\/mol.109.055830","article-title":"Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria","volume":"76","author":"Hermanson","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/1535-7163.1513.3.12","article-title":"The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism","volume":"3","author":"Pei","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/mp7000846","article-title":"Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4h-chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis","volume":"4","author":"Doshi","year":"2007","journal-title":"Mol. Pharm."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.canlet.2007.10.012","article-title":"Sha 14-1, a stable and ros-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell","volume":"259","author":"Tian","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1021\/jm060460o","article-title":"Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins","volume":"49","author":"Wang","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/jso.21012","article-title":"Chemotherapy in the treatment of locally advanced head and neck cancer","volume":"97","author":"Forastiere","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_105","first-page":"6","article-title":"Efficiency of recombinant human TNF in human cancer therapy","volume":"6","author":"Lejeune","year":"2006","journal-title":"Cancer Immun."},{"key":"ref_106","first-page":"4087","article-title":"A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors","volume":"20","author":"Nakamoto","year":"2000","journal-title":"Anticancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.yexcr.2013.12.007","article-title":"BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma","volume":"322","author":"Lieber","year":"2014","journal-title":"Exp. Cell Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.21054","article-title":"Hdac inhibitor treatment of hepatoma cells induces both trail-independent apoptosis and restoration of sensitivity to trail","volume":"43","author":"Pathil","year":"2006","journal-title":"Hepatology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1126\/science.1071553","article-title":"The fas signaling pathway: More than a paradigm","volume":"296","author":"Wajant","year":"2002","journal-title":"Science"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"L607","DOI":"10.1152\/ajplung.00390.2009","article-title":"Opposing effects of bim and Bcl-2 on lung endothelial cell migration","volume":"299","author":"Grutzmacher","year":"2010","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jcp.20858","article-title":"Bcl-2 expression modulates cell adhesion and migration promoting branching of ureteric bud cells","volume":"210","author":"Sheibani","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e76446","DOI":"10.1371\/journal.pone.0076446","article-title":"Beyond cell death\u2014Antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro","volume":"8","author":"Koehler","year":"2013","journal-title":"PLoS One"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.yexcr.2013.01.024","article-title":"BH3 mimetics reduce adhesion and migration of hepatoblastoma and hepatocellular carcinoma cells","volume":"319","author":"Vogt","year":"2013","journal-title":"Exp. Cell Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1158\/1078-0432.CCR-04-1162","article-title":"Elevated expression of Wnt antagonists is a common event in hepatoblastomas","volume":"11","author":"Koch","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/mpo.1280","article-title":"Prognostic impact of molecular genetic alterations in hepatoblastoma","volume":"38","author":"Kraus","year":"2002","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-10-0822","article-title":"Phase i dose finding studies of obatoclax (Gx15\u2013070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced solid tumors or lymphoma","volume":"16","author":"Hwang","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1158\/1078-0432.CCR-08-0999","article-title":"A phase i study of the pan Bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies","volume":"14","author":"Schimmer","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.lungcan.2014.05.003","article-title":"Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer","volume":"85","author":"Langer","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective Bcl-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00280-014-2530-9","article-title":"Mechanism-based pharmacokinetic\/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia","volume":"74","author":"Kaefer","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_121","first-page":"1","article-title":"ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib, and JQ1 in \u201cdouble hit\u201d lymphoma cells","volume":"1","author":"Veliz","year":"2014","journal-title":"Leukemia Lymphoma"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of Bcl-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/cdd.2014.105","article-title":"Elimination of quiescent\/slow-proliferating cancer stem cells by Bcl-xl inhibition in non-small cell lung cancer","volume":"21","author":"Zeuner","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ccr.2013.01.018","article-title":"ABT-199: Taking dead aim at Bcl-2","volume":"23","author":"Davids","year":"2013","journal-title":"Cancer Cell"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/2\/4190\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:42:45Z","timestamp":1760215365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/2\/4190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,16]]},"references-count":124,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2]]}},"alternative-id":["ijms16024190"],"URL":"https:\/\/doi.org\/10.3390\/ijms16024190","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,16]]}}}